Podcast: Look Ahead To PCSK9 Inhibitors With “The Pink Sheet” Editors
Executive Summary
Editors provide background on the PCSK9 inhibitor class of biologics that are nearing FDA approval, including FDA advisory committee reviews, commercialization plans and concerns about cost from payers.